Anzeige
Meldung des Tages: Gold dreht wieder auf: Goldpreis-Comeback – und diese Bohrung liefert 307 Meter „Gold-System“

ELEVATE INC News

Aktie
WKN:  ISIN:  US2862171046 US-Symbol:  ELEV
Keine aktuellen Kursdaten verfügbar
Depot/Watchlist
Dieses Wertpapier ist nicht mehr handelbar.
Marktkapitalisierung *
-
Streubesitz
-
KGV
-
Index-Zuordnung
-

ELEVATE INC News

12.06.25 - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KNW, ELEV, CRKN on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KNW, ELEV, CRKN on Behalf of Shareholders PR Newswire
09.06.25 - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FLS, KNW, ELEV, CRKN on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FLS, KNW, ELEV, CRKN on Behalf of Shareholders PR Newswire
09.06.25 - PR Newswire
Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right
Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right PR Newswire
15.05.25 - PR Newswire
Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates PR Newswire
25.04.25 - PR Newswire
Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
Elevation Oncology Presents Preclinical Proof-​of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025 PR Newswire
25.03.25 - PR Newswire
Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025 PR Newswire
06.03.25 - PR Newswire
Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements
Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements PR Newswire
25.02.25 - PR Newswire
Elevation Oncology to Participate in Upcoming Investor Conferences
Elevation Oncology to Participate in Upcoming Investor Conferences PR Newswire
13.01.25 - PR Newswire
Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones
Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones PR Newswire
12.12.24 - PR Newswire
Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors
Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors PR Newswire
26.11.24 - PR Newswire
Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference
Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference PR Newswire
06.11.24 - PR Newswire
Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements
Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements PR Newswire
23.09.24 - PR Newswire
Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2
Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction ...
03.09.24 - PR Newswire
Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference PR Newswire
27.06.24 - PR Newswire
Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer
Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer PR Newswire
07.05.24 - PR Newswire
Elevation Oncology to Present at the Citizens JMP Life Sciences Conference
Elevation Oncology to Present at the Citizens JMP Life Sciences Conference PR Newswire
02.05.24 - PR Newswire
Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements
Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements PR Newswire
08.04.24 - PR Newswire
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
Elevation Oncology Presents Preclinical Proof-​of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024 PR Newswire
06.03.24 - PR Newswire
Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements
Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements PR Newswire
05.03.24 - PR Newswire
Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024
Elevation Oncology to Present Preclinical Proof-​of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024 PR Newswire

Newssuche

Videos

newspaper
03.02.26
2026 02 03 17 34 Trendjumper Einführung
Zunächst inormieren wir unsere Stammkunden bezüglich des bevorstehenden Seminars und bieten für ... Mehr »